Factors Associated with Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology

Ji Young Park; Tae Joo Jeon

doi:10.5946/ce.2018.105

Articles

Page Path: HOME > Clin Endosc > Volume 52(2); 2019 > Article

Original Article Factors Associated with Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology: Ji Young Park, Tae Joo Jeon^,; Clinical Endoscopy 2019;52(2):168-174.
DOI: https://doi.org/10.5946/ce.2018.105
Published online: January 9, 2019

Division of Gastroenterology, Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea

Correspondence: Tae Joo Jeon Division of Gastroenterology, Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Sanggye Paik Hospital, 1342 Dongil-ro, Nowon-gu, Seoul 01757, Korea Tel: +82-10-5397-8971, Fax: +82-2-950-1955, E-mail: drjtj@paik.ac.kr

• Received: June 15, 2018 • Revised: August 25, 2018 • Accepted: September 17, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

5,829 Views
91 Download
5 Web of Science
5 Crossref
5 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

See letter "How Can We Differentiate Malignant Biliary Strictures from Clinically Indeterminate Biliary Strictures?" in Volume 52 on page 95.

Abstract

Background/Aims
Pathological diagnosis of biliary strictures with atypical or suspicious cells on endoscopic retrograde brush cytology and indeterminate strictures on imaging is challenging. The aim of this study was to identify markers for malignant strictures in such cases.
Methods
We retrospectively analyzed data collected from 146 consecutive patients with indeterminate biliary strictures on imaging who underwent endoscopic retrograde brush cytology from 2007 to 2013. Factors associated with malignant strictures in patients with atypical or suspicious cells on brush cytology were identified.
Results
Among the 67 patients with a malignant disease (48 cholangiocarcinoma, 6 gallbladder cancer, 5 pancreatic cancer, 5 ampulla of Vater cancer, and 3 other types), 36 (53.7%) had atypical or suspicious cells on brush cytology. Among these, the factors that independently correlated with malignant strictures were stricture length (odds ratio [OR], 5.259; 95% confidence interval [CI], 1.802– 15.294) and elevated carbohydrate antigen 19-9 (CA19-9) (OR, 3.492; 95% CI, 1.242–9.815), carcinoembryonic antigen (CEA) (OR, 4.909; 95% CI, 1.694–14.224), alkaline phosphatase (ALP) (OR, 3.362; 95% CI, 1.207–9.361), and gamma-glutamyl transpeptidase (rGT) (OR, 4.318; 95% CI, 1.512–12.262).
Conclusions
Elevated levels of CA19-9, CEA, ALP, and rGT and stricture length are associated with malignant strictures in patients with indeterminate biliary strictures on imaging and atypical or suspicious cells on brush cytology.
Keywords: Brush cytology; Biliary stricture; Atypical cell; Suspicious cell

INTRODUCTION

Biliary strictures are byproducts of benign and malignant diseases involving the biliary tree, pancreas, gallbladder, or ampulla [1-4]. Accurate pathological diagnosis of biliary strictures remains clinically challenging, but is essential for choosing the correct treatment [4,5]. As an alternative to biopsy, which is hampered by the limited accessibility of the strictures and prone to complications such as tumor seeding, brush cytology is a simple and safe means of sampling biliary strictures [1,2]. Brush cytology is widely available; it is performed during endoscopic retrograde cholangiopancreatography (ERCP), and the diagnostic specificity of endoscopic retrograde brush cytology (ERBC) is 100% or near 100% [5]. However, its sensitivity is relatively low and variable, ranging from 18% to 80% [1-7]. This may reflect the inherent properties of the tumor (its submucosal location, often fibrotic content, and inability to invade the ductal epithelium) and the extrinsic compressions leading to the stricture, which are not sampled by the brush [5]. Hence, the results may be ambiguous, which confounds the treatment and management of the stricture.

Brush cytology samples are classified into four categories based on the type of cells comprising the stricture: benign, atypical, suspicious for malignancy, and malignant. Strictures with malignant cells are usually considered malignant and are treated as such [5]. Those with atypical or suspicious cells may or may not be malignant; hence, their management is difficult and confusing, especially when biliary strictures are also indeterminate on imaging tests [5].

The objective of this study was to identify the factors associated with malignant biliary strictures in patients with atypical or suspicious cells on ERBC and indeterminate biliary strictures on imaging.

MATERIALS AND METHODS

Patients

Data were collected by retrospectively reviewing the medical records of 146 consecutive patients with indeterminate biliary strictures on imaging who underwent brush cytology at the Sanggye Paik Hospital from March 2007 to December 2013. An indeterminate biliary stricture was defined as follows: (1) no identifiable mass on computed tomography (CT), transabdominal ultrasound, endoscopic ultrasound (EUS), or magnetic resonance imaging (MRI); (2) no distant metastasis on CT, transabdominal ultrasound, or MRI; and (3) no recent history (<3 months) of traumatic or iatrogenic bile duct injury. A biliary stricture was diagnosed as malignant if indicated by the pathology of a biopsy or surgical specimen or the imaging findings during the follow-up period. A stricture was diagnosed as benign if indicated by the tissue sampling results and if there was no evidence of a tumor mass during a follow-up period of at least 2 years. In patients with multiple brush samples, only the samples obtained at the initial ERCP were evaluated.

Data were collected from the electronic medical records using a standardized data collection form. The final diagnosis of the disease that caused the biliary stricture was based on the integration of pathologic and cytologic results of an additional endoscopic biopsy, a fine-needle aspiration (FNA) sample, or a surgical sample during the follow up. This study was approved by the Inje University Sanggye Paik Hospital Institutional Review Board (SGPAIK 2015-12-014).

Brush sampling procedure and interpretation of the results

The cytology samples were collected by using a Microvasive Rapid Exchange cytology brush (Boston Scientific, Natick, MA, USA) with a standard 0.035-inch guidewire. The brush sampling procedure at our institution is standardized, with brushings obtained prior to biliary dilation or biopsy. The brush was inserted into the duct of interest over the guidewire and positioned just distal to the stricture. It was then advanced from the sheath to a point proximal to the stricture and moved across the stricture in a to-and-fro manner 20 times. Lastly, it was withdrawn into the sheath and, along with the guidewire, removed from the endoscope. The brush segment of the brushing device was cut from the supporting wire, placed in ThinPrep CytoLyt solution (Cytyc Corp, Marlborough, MA, USA), and transported to the cytology laboratory.

To obtain the final cytological diagnosis, smears and precipitates from perfused saline were fixed in 95% ethanol and stained by using Papanicolaou’s method. Samples were classified as follows: no abnormal cells (benign), atypical cells, suspicious cells, or malignant cells. Patients with atypical or suspicious cells were included in our study.

Study variables and definitions

The factors studied included age; sex; smoking status; alcohol intake; body mass index; length and location of the stricture; diameter of the upstream dilated bile duct; weight loss at the time of brushing; final diagnosis and type of cancer in cases of malignancy; presence of diabetes; presence of clinical jaundice; and presence of acute cholangitis, a gallbladder stone, or a bile duct stone on CT or transabdominal ultrasound. Jaundice was defined as a serum bilirubin level >2.0 mg/dL. Weight loss was defined as a ≥10% decrease in usual body weight during the 6 months prior to brushing. Alcohol intake was defined as consumption of >1 drink (>13 g) per day for at least 1 year. Laboratory parameters included serum bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (rGT), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) levels.

Statistical analysis

Categorical variables were analyzed by using the chi-square test or Fisher’s exact test. Continuous variables, presented as mean±standard deviation, were analyzed by using the Mann-Whitney test. Variables in patients with malignant versus benign biliary strictures were compared via univariate analysis; this comparison was limited to patients with atypical or suspicious cells on brush cytology. Variables deemed significant in the univariate analysis were evaluated via multivariate logistic regression analysis to identify those independently associated with malignant strictures. The 95% confidence intervals (CIs) for sensitivity, specificity, positive and negative predictive values, and false negative and false positive rates were calculated. The optimal cut-off values of meaningful factors associated with malignant biliary stricture were computed by using the trade-off between sensitivity and specificity on the receiver-operating characteristic (ROC) curves, and the accuracy of prediction of the malignant stricture was estimated using the area under the receiver-operating curve. A p-value of <0.05 was the significance threshold for all tests. All statistical analyses were performed by using SPSS software, version 24.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

Overall data

A total of 146 patients with indeterminate biliary strictures and ERBC samples were included in our study, 67 with malignant disease and 79 with benign disease. The basal characteristics of all enrolled patients are shown in Table 1. Cholangiocarcinoma (48 patients) was the most common cancer type in patients with malignant disease, followed by gallbladder cancer (six patients), pancreatic cancer (five patients), ampulla of Vater cancer (five patients), and other types (three patients). The cancer type did not significantly affect the brush cytology results. Thirty-six (53.7%) patients with malignant disease had atypical or suspicious cells on ERBC, 12 (17.9%) had malignant cells, and 19 (28.3%) had no abnormal cells. In contrast, only 29 (19.0%) patients with benign disease had atypical or suspicious cells and none had malignant cells (Table 2). The specimen of all patients were sufficient to be tested.

Overall, the sensitivity, specificity, positive predictive value, and negative predictive value of brush cytology for diagnosis of biliary strictures were 71.6% (95% CI, 59.1–81.6), 63.3% (95% CI, 51.6–73.6), 62.3% (95% CI, 51.1–72.3), and 72.5% (95% CI, 60.5–81.6), respectively. The false positive rate was 37.7% (95% CI, 27.1–49.4), and the false negative rate was 27.5% (95% CI, 17.8–39.8).

Univariate analysis

Patients who with atypical or suspicious cells on brush cytology were divided into two groups: those with malignant strictures and those with benign strictures. Several variables were compared between the two groups via univariate analysis during the follow-up period (Table 3). Variables that differed significantly between the groups were presence of a gallbladder stone, presence of a bile duct stone, stricture length, and levels of ALP, total bilirubin, rGT, CEA, and CA19-9.

Multivariate logistic regression analysis

On multivariate logistic regression analysis, the independent predictors of a malignant stricture were as follows: elevated CA19-9 level (odds ratio [OR], 3.49; 95% CI, 1.24–9.81; p=0.018), elevated CEA level (OR, 4.90; 95% CI, 1.69–14.22; p=0.003), elevated ALP level (OR, 3.36; 95% CI, 1.20–9.36; p=0.02), elevated rGT level (OR, 4.31; 95% CI, 1.52–12.26; p=0.006), and long strictures (OR 5.25, 95% CI 1.80–15.29; p=0.002) (Table 4). The ROCs for the independent predictors of malignant stricture (CA19-9, CEA, ALP, rGT, and length of stricture) are shown in Fig. 1. On the basis of the highest sensitivity and specificity values generated from the ROC, we generated the optimal cut-off values of each factors for predicting the malignancy (Table 5).

DISCUSSION

Benign and malignant diseases of the biliary tract can cause biliary strictures and, in turn, cholangitis and jaundice [1,2,7-9]. Most biliary strictures can be identified via imaging modalities such as CT, ultrasound, and MRI, with additional information provided by EUS for less prominent strictures [5,10-14]. However, strictures are difficult to diagnose if there is no definite causative lesion such as a mass, a stone, or inflammation [5]. Brush cytology during ERCP is an established technique for evaluating biliary strictures [3,8,15]. It has a relatively high specificity but a low and broad-range sensitivity [5]. In particular, because of desmoplastic reactions or fibrosis, which are common in pancreatobiliary malignancies, it is unclear whether strictures with atypical or suspicious cells on brush cytology are malignant [5]. When such strictures are also indeterminate on imaging, it is also unclear what additional diagnostic tests are required and how long and at what intervals follow-up examinations should be performed.

EUS-FNA is an alternative technique for pathological diagnosis of biliary strictures [10,16]. However, the results are operator-dependent and targeting is difficult when strictures are small [1,2]. Moreover, when strictures are malignant, there is the possibility of tumor seeding via the needle tract [1]. Therefore, identification of the factors associated with malignant strictures would facilitate diagnosis and allow us to follow patients at high risk. In the study by Navaneethan et al., the presence of clinical jaundice, current alcohol consumption, and an elevated CA19-9 level (>33 U/mL) at the time of ERBC independently predicted an increased risk of cancer during the follow-up period in patients with atypical cells [5].

According to our data, the diagnostic sensitivity of brush cytology in the 146 patients enrolled in this study was 71.6%, which is similar to previously published values (18% to 80%), whereas the specificity was lower than in other studies (63.3% versus nearly 100%). The difference in the sensitivity values may reflect the inclusion of patients with atypical or suspicious cells as well as malignant cells in our study.

Factors that differed significantly in patients with malignant versus benign biliary strictures in our univariate analysis were presence of a gallbladder stone, presence of a bile duct stone, a long stricture, and elevated ALP, total bilirubin, rGT, CEA, and CA19-9 levels. Among these, stricture length was the strongest independent predictor of malignancy in our multivariate analysis (OR, 5.3; 95% CI, 1.8–15.3; p=0.002). According to Park et al., extrahepatic cholangiocarcinomas have an infiltrative growth pattern, and thus it is necessary to distinguish them from benign strictures [13]. Factors facilitating differentiation include the margin (irregular or smooth), symmetry (symmetric or asymmetric), and shape (abrupt or gradual narrowing) [13]. Notably, Park et al. found that the malignant and benign strictures differed significantly in length [13].

Elevated levels of CA19-9, CEA, ALP, and rGT were also independently associated with malignant strictures in our multivariate analysis. CA19-9 is a well-known, helpful biomarker for pancreatobiliary cancer and its prognosis [17-19]. However, CA19-9 levels may stay normal in early or localized cancers and increased in benign diseases such as cholangitis and choledocholithiasis [17,19]. CEA is a well-establisheed biomarker for gastrointestinal tract and pulmonary cancer, as well as a prognostic factor for cholangiocarcinoma [18]. As reported by Li et al., co-detection of CEA and alpha-fetoprotein or CA 125 is more diagnostically accurate than detection of CA19-9 alone [18].

ALP resides in hepatic sinusoidal and biliary canalicular membranes and is overexpressed in cholestatic diseases [20]. Several studies have shown that patients with malignant strictures or cholangiocarcinomas have higher levels of ALP than those with benign biliary diseases such as gallstones [20]. This finding dovetails with our results identifying ALP as a diagnostic marker for malignant biliary strictures. As an explanation for the association between ALP levels and malignant strictures, we note that biliary duct obstructions due to malignant strictures tend to be more complete and prolonged than those due to benign causes, such as biliary stones (in which the size of the obstructions fluctuates owing to the movement of the stone) [21].

rGT is normally present in the membranes of liver, bile duct, lung, pancreas, brain, gallbladder, and kidney tissues and heart muscles [22]. Why rGT levels are increased in malignant strictures is not known; however, we suggest the progressive and chronic changes associated with cancerogenesis result in severe biliary dysfunction [22].

We also identified gallbladder stones (OR, 0.1; 95% CI, 0.0–0.5; p=0.002) and bile duct stones (OR, 0.1; 95% CI, 0.0–0.2; p=0.000) as negative predictive factors for malignant biliary strictures. Owing to inflammation, a stricture is more likely to be benign when a stone is present.

Our study has two limitations: its retrospective design and its small number of patients. Patient number was limited by the performance of the study at a single center and the exclusion of patients who died from other causes during the study period or who were followed up at other hospitals. Despite these limitations, our study is valuable because it is one of only a few previous studies on indeterminate biliary strictures on imaging and atypical or suspicious cells on brush cytology.

The appropriate management and follow-up strategies for patients with atypical or suspicious cells on brush cytology and indeterminate biliary strictures on imaging have not yet been determined. Identification of markers for malignant biliary strictures will facilitate diagnoses in these patients, hence ensuring proper management and eliminating unnecessary and sometimes costly follow-up procedures.

Conflicts of Interest:The authors have no financial conflicts of interest.

Fig. 1.

Receiver operator curves and corresponding area under curves for carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (rGT) and length of stricture.

Table 1.

Basal Characteristics of the 146 Patients in Our Study

Variables, n (%)	Value
Male gender	86 (58.9)
Age (yr, mean±SD)	66.9±12.6
BMI (kg/m², mean±SD)	22.5±2.9
Diabetes mellitus	32 (21.9)
Smokers	31 (21.2)
Alcoholic	47 (32.2)
Clinical presentations
GB/CBD stone	69 (47.3)
Cholangitis	100 (68.5)
Jaundice	98 (67.1)
Weight loss	25 (17.1)
Laboratory values (mean±SD)
AST (U/L)	169.9±223.3
ALT (U/L)	174.6±218.3
ALP (U/L)	312.0±295.4
Total bilirubin (mg/dL)	6.1±7.0
rGT (U/L)	437.4±422.8
CEA (ng/mL)	2.6±4.0
CA19-9 (U/mL)	1,219.2±2,800.2
Elevated CA19-9 (>37 U/mL)	85 (58.2)
Length of stricture (mm, mean±SD)	19.8±15.7
Location of stricture
Upper third	81 (55.5)
Middle third	35 (24.0)
Lower third	30 (20.5)
Final diagnosis
Benign stricture	79 (54.1)
Pancreatic cancer	5 (3.4)
Cholangiocarcinoma	48 (32.9)
AOV cancer	5 (3.4)
GB cancer	6 (4.1)
Others	3 (2.1)
Detection of cancer	67 (45.9)

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AOV, ampulla of Vater; AST, aspartate aminotransferase; BMI, body mass index; CA19-9, carbohydrate antigen 19-9; CBD, common bile duct; CEA, carcinoembryonic antigen; GB, gallbladder; rGT, gamma-glutamyl transpeptidase; SD, standard deviation.

Table 2.

Brush Cytology Results

	Benign (n=79)	Malignant (n=67)
No abnormal cells (n, %)	50 (63.3)	19 (28.3)
Atypical cells (n, %)	25 (31.6)	20 (29.9)
Suspicious cells (n, %)	4 (5.1)	16 (23.9)
Malignant cells (n, %)	0 (0)	12 (17.9)
Sensitivity	71.6% (95% CI, 59.1–81.6)
Specificity	63.3% (95% CI, 51.6–73.6)
Positive predictive value	62.3% (95% CI, 51.1–72.3)
Negative predictive value	72.5% (95% CI, 60.5–81.6)

CI, confidence interval.

Table 3.

Univariate Comparisons between Benign and Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology

	Benign (n=29)	Malignant (n=36)	p-value
Gender (male, %)	14 (48.3)	24 (66.7)	0.107
Age (yr, mean±SD)	66.76±17.09	69.86±11.81	0.391
Jaundice (n, %)	20 (69.0)	30 (83.3)	0.142
Cholangitis (n, %)	23 (79.3)	21 (58.3)	0.109
Weight loss (n, %)	4 (13.8)	8 (22.2)	0.294
BMI (kg/m²)	21.69±3.05	23.07±2.70	0.057
GB stone (n, %)	14 (48.3)	4 (11.1)	0.002
BD stone (n, %)	18 (62.1)	3 (8.3)	0.000
Alcohol (n, %)	11 (37.9)	10 (27.8)	0.273
Smoking (n, %)	3 (10.3)	7 (19.4)	0.256
Diabetes mellitus (n, %)	4 (13.8)	9 (25.0)	0.210
Laboratory values (mean±SD)
AST (U/L)	202.97±166.90	158.72±144.16	0.256
ALT (U/L)	202.41±189.82	169.38±153.09	0.448
ALP (U/L)	231.45±163.68	411.75±285.57	0.004
total bilirubin (mg/dL)	3.23±2.29	8.70±8.48	0.001
rGT (U/L)	312.91±271.02	596.72±527.17	0.011
CEA (ng/mL)	1.49±1.78	3.96±5.34	0.017
CA19-9 (U/mL)	91.02±272.22	1,682±3,155.64	0.005
Length of stricture (mm, mean±SD)	14.86±14.83	25.83±15.33	0.005
Location of stricture (lower/mid/upper, %)	10.3/31.0/58.6	27.8/25.0/47.2	0.145
Upstream bile duct diameter (mm, mean±SD)	11.0±3.5	13.0±4.3	0.449

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BD, bile duct; BMI, body mass index; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; GB, gallbladder; rGT, gamma-glutamyl transpeptidase; SD, standard deviation.

Table 4.

Variables Associated with Malignant Strictures

	odds ratio	95% CI	p-value
GB stone	0.134	0.038–0.477	0.002
BD stone	0.056	0.014–0.225	0.000
CA19-9	3.492	1.242–9.815	0.018
CEA	4.909	1.694–14.224	0.003
t.Bil	2.506	0.918–6.842	0.073
ALP	3.362	1.207–9.361	0.020
rGT	4.318	1.521–12.262	0.006
Length of stricture	5.250	1.802–15.294	0.002

ALP, alkaline phosphatase; BD, bile duct; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; GB, gallbladder; rGT, gamma-glutamyl transpeptidase; t.Bil, total bilirubin.

Table 5.

The Optimal Cut-Off Values of CA19-9, CEA, ALP, rGT and Length of Stricture

	AuC (95% CI)	Cut-off value	Sensitivity	Specificity
CA19-9	0.729 (0.649–0.811)	56.44 U/mL	73.1%	64.6%
CEA	0.750 (0.673–0.828)	1.51 ng/mL	79.1%	58.7%
ALP	0.736 (0.654–0.817)	200.5 U/L	76.1%	60.8%
rGT	0.706 (0.620–0.791)	297.0 U/L	74.6%	63.3%
Length of stricture	0.791 (0.717–0.865)	14.5 mm	74.6%	74.7%

ALP, alkaline phosphatase; AUC, area under curve; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; rGT, gamma-glutamyl transpeptidase.

REFERENCES

1. Mahmoudi N, Enns R, Amar J, AlAli J, Lam E, Telford J. Biliary brush cytology: factors associated with positive yields on biliary brush cytology. World J Gastroenterol 2008;14:569–573.Article PubMed PMC
2. Tanaka H, Matsusaki S, Baba Y, et al. Usefulness of endoscopic transpapillary tissue sampling for malignant biliary strictures and predictive factors of diagnostic accuracy. Clin Endosc 2018;51:174–180.Article PubMed PMC PDF
3. Parsi MA, Deepinder F, Lopez R, Stevens T, Dodig M, Zuccaro G. Factors affecting the yield of brush cytology for the diagnosis of pancreatic and biliary cancers. Pancreas 2011;40:52–54.Article PubMed
4. Kawada N, Uehara H, Katayama K, et al. Combined brush cytology and stent placement in a single session for presumed malignant biliary stricture. J Gastroenterol Hepatol 2011;26:1247–1251.Article PubMed
5. Navaneethan U, Singh T, Gutierrez NG, et al. Predictors for detection of cancer in patients with indeterminate biliary stricture and atypical cells on endoscopic retrograde brush cytology. J Dig Dis 2014;15:268–275.Article PubMed
6. Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2015;81:168–176.Article PubMed PMC
7. Victor DW, Sherman S, Karakan T, Khashab MA. Current endoscopic approach to indeterminate biliary strictures. World J Gastroenterol 2012;18:6197–6205.Article PubMed PMC
8. Lee HJ, Cho KB. Diagnosis of malignant biliary stricture: more is better. Clin Endosc 2018;51:115–117.Article PubMed PMC PDF
9. Temiño López-Jurado R, Cacho Acosta G, Argüelles Pintos M, Rodríguez Caravaca G, Lledó Navarro JL, Fernández Rodríguez C. Diagnostic yield of brush cytology for biliary stenosis during ERCP. Rev Esp Enferm Dig 2009;101:385–389, 390-394.Article PubMed
10. Papachristou GI, Smyrk TC, Baron TH. Endoscopic retrograde cholangiopancreatography tissue sampling: when and how? Clin Gastroenterol Hepatol 2007;5:783–790.Article PubMed
11. Ohshima Y, Yasuda I, Kawakami H, et al. EUS-FNA for suspected malignant biliary strictures after negative endoscopic transpapillary brush cytology and forceps biopsy. J Gastroenterol 2011;46:921–928.Article PubMed PDF
12. Fritcher EG, Kipp BR, Halling KC, et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology 2009;136:2180–2186.Article PubMed
13. Park MS, Kim TK, Kim KW, et al. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology 2004;233:234–240.Article PubMed
14. Baron TH, Harewood GC, Rumalla A, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004;2:214–219.Article PubMed
15. Stewart CJ, Mills PR, Carter R, et al. Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases. J Clin Pathol 2001;54:449–455.Article PubMed PMC
16. DeWitt J, Misra VL, Leblanc JK, McHenry L, Sherman S. EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointest Endosc 2006;64:325–333.Article PubMed
17. Liang B, Zhong L, He Q, et al. Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis. Med Sci Monit 2015;21:3555–3563.Article PubMed PMC
18. Li Y, Li DJ, Chen J, et al. Application of joint detection of AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma. Asian Pac J Cancer Prev 2015;16:3451–3455.Article PubMed PDF
19. Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 2004;10:427–432.Article PubMed PMC
20. Zare M, Kargar S, Akhondi M, Mirshamsi MH. Role of liver function enzymes in diagnosis of choledocholithiasis in biliary colic patients. Acta Med Iran 2011;49:663–666.PubMed
21. Hayat JO, Loew CJ, Asrress KN, McIntyre AS, Gorard DA. Contrasting liver function test patterns in obstructive jaundice due to biliary strictures [corrected] and stones. QJM 2005;98:35–40.Article PubMed PDF
22. Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev Clin Lab Sci 1980;12:1–58.Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

High Diagnostic Yield of Endoscopic Retrograde Cholangiopancreatography Brush Cytology for Indeterminate Strictures
Abdulsemed M Nur, Misbah Salim, Scott Boerner, Suqing Li, Cindy C Y Law, Leanne Edwards, Kaitlin Ryan, Paul D James
Journal of the Canadian Association of Gastroenterology.2022; 5(5): 234. CrossRef
Digital Image Analysis has an Additive Beneficial Role to Conventional Cytology in Diagnosing the Nature of Biliary Ducts Stricture
Ahmed Helmy, Heba Mohamed Saad Eldien, Gehan Sayed Seifeldein, Ahmed Mohammed Abu-Elfatth, Adnan Ahmed Mohammed
Journal of Clinical and Experimental Hepatology.2021; 11(2): 209. CrossRef
Predicting Malignancy of Biliary Stricture with a Nomogram in Patients with a Non-Malignant Endoscopic Tissue Diagnosis: A Retrospective Study
Yizhen Zhang, Qingwei Jiang, Qiang Wang, Yunlu Feng, Dongsheng Wu, Tao Guo, Shengyu Zhang, Xi Chen, Yingyun Yang, Wen Shi, Xi Wu, Aiming Yang
Cancer Management and Research.2021; Volume 13: 7735. CrossRef
Tips and tricks for the diagnosis and management of biliary stenosis-state of the art review
Giovanna Del Vecchio Blanco, Michelangela Mossa, Edoardo Troncone, Renato Argirò, Andrea Anderloni, Alessandro Repici, Omero Alessandro Paoluzi, Giovanni Monteleone
World Journal of Gastrointestinal Endoscopy.2021; 13(10): 473. CrossRef
How Can We Differentiate Malignant Biliary Strictures from Clinically Indeterminate Biliary Strictures?
Eui Joo Kim, Jae Hee Cho
Clinical Endoscopy.2019; 52(2): 95. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Factors Associated with Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology

Clin Endosc. 2019;52(2):168-174. Published online January 9, 2019

DOI: https://doi.org/10.5946/ce.2018.105

XML Download

Figure

Factors Associated with Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology

Fig. 1. Receiver operator curves and corresponding area under curves for carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (rGT) and length of stricture.

Fig. 1.

Factors Associated with Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology

Variables, n (%)	Value
Male gender	86 (58.9)
Age (yr, mean±SD)	66.9±12.6
BMI (kg/m², mean±SD)	22.5±2.9
Diabetes mellitus	32 (21.9)
Smokers	31 (21.2)
Alcoholic	47 (32.2)
Clinical presentations
GB/CBD stone	69 (47.3)
Cholangitis	100 (68.5)
Jaundice	98 (67.1)
Weight loss	25 (17.1)
Laboratory values (mean±SD)
AST (U/L)	169.9±223.3
ALT (U/L)	174.6±218.3
ALP (U/L)	312.0±295.4
Total bilirubin (mg/dL)	6.1±7.0
rGT (U/L)	437.4±422.8
CEA (ng/mL)	2.6±4.0
CA19-9 (U/mL)	1,219.2±2,800.2
Elevated CA19-9 (>37 U/mL)	85 (58.2)
Length of stricture (mm, mean±SD)	19.8±15.7
Location of stricture
Upper third	81 (55.5)
Middle third	35 (24.0)
Lower third	30 (20.5)
Final diagnosis
Benign stricture	79 (54.1)
Pancreatic cancer	5 (3.4)
Cholangiocarcinoma	48 (32.9)
AOV cancer	5 (3.4)
GB cancer	6 (4.1)
Others	3 (2.1)
Detection of cancer	67 (45.9)

	Benign (n=79)	Malignant (n=67)
No abnormal cells (n, %)	50 (63.3)	19 (28.3)
Atypical cells (n, %)	25 (31.6)	20 (29.9)
Suspicious cells (n, %)	4 (5.1)	16 (23.9)
Malignant cells (n, %)	0 (0)	12 (17.9)
Sensitivity	71.6% (95% CI, 59.1–81.6)
Specificity	63.3% (95% CI, 51.6–73.6)
Positive predictive value	62.3% (95% CI, 51.1–72.3)
Negative predictive value	72.5% (95% CI, 60.5–81.6)

	Benign (n=29)	Malignant (n=36)	p-value
Gender (male, %)	14 (48.3)	24 (66.7)	0.107
Age (yr, mean±SD)	66.76±17.09	69.86±11.81	0.391
Jaundice (n, %)	20 (69.0)	30 (83.3)	0.142
Cholangitis (n, %)	23 (79.3)	21 (58.3)	0.109
Weight loss (n, %)	4 (13.8)	8 (22.2)	0.294
BMI (kg/m²)	21.69±3.05	23.07±2.70	0.057
GB stone (n, %)	14 (48.3)	4 (11.1)	0.002
BD stone (n, %)	18 (62.1)	3 (8.3)	0.000
Alcohol (n, %)	11 (37.9)	10 (27.8)	0.273
Smoking (n, %)	3 (10.3)	7 (19.4)	0.256
Diabetes mellitus (n, %)	4 (13.8)	9 (25.0)	0.210
Laboratory values (mean±SD)
AST (U/L)	202.97±166.90	158.72±144.16	0.256
ALT (U/L)	202.41±189.82	169.38±153.09	0.448
ALP (U/L)	231.45±163.68	411.75±285.57	0.004
total bilirubin (mg/dL)	3.23±2.29	8.70±8.48	0.001
rGT (U/L)	312.91±271.02	596.72±527.17	0.011
CEA (ng/mL)	1.49±1.78	3.96±5.34	0.017
CA19-9 (U/mL)	91.02±272.22	1,682±3,155.64	0.005
Length of stricture (mm, mean±SD)	14.86±14.83	25.83±15.33	0.005
Location of stricture (lower/mid/upper, %)	10.3/31.0/58.6	27.8/25.0/47.2	0.145
Upstream bile duct diameter (mm, mean±SD)	11.0±3.5	13.0±4.3	0.449

	odds ratio	95% CI	p-value
GB stone	0.134	0.038–0.477	0.002
BD stone	0.056	0.014–0.225	0.000
CA19-9	3.492	1.242–9.815	0.018
CEA	4.909	1.694–14.224	0.003
t.Bil	2.506	0.918–6.842	0.073
ALP	3.362	1.207–9.361	0.020
rGT	4.318	1.521–12.262	0.006
Length of stricture	5.250	1.802–15.294	0.002

	AuC (95% CI)	Cut-off value	Sensitivity	Specificity
CA19-9	0.729 (0.649–0.811)	56.44 U/mL	73.1%	64.6%
CEA	0.750 (0.673–0.828)	1.51 ng/mL	79.1%	58.7%
ALP	0.736 (0.654–0.817)	200.5 U/L	76.1%	60.8%
rGT	0.706 (0.620–0.791)	297.0 U/L	74.6%	63.3%
Length of stricture	0.791 (0.717–0.865)	14.5 mm	74.6%	74.7%

Table 1. Basal Characteristics of the 146 Patients in Our Study

Table 2. Brush Cytology Results

CI, confidence interval.

Table 3. Univariate Comparisons between Benign and Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology

Table 4. Variables Associated with Malignant Strictures

Table 5. The Optimal Cut-Off Values of CA19-9, CEA, ALP, rGT and Length of Stricture

ALP, alkaline phosphatase; AUC, area under curve; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; rGT, gamma-glutamyl transpeptidase.